Fintan Kelleher is the Director of the Centre for AMR and One-Health Research (CAMROH) and leader of the Molecular Design & Synthesis Group, with over 30 years of experience in research in both Industrial and Academic settings. From 1991-1997 he was a Senior Research Chemist in the Medicinal Chemistry Department of the Neuroscience Research Centre of MSD, UK. There he worked on projects related to diseases of the CNS and was part of the team which developed Emend®, for Chemotherapy-Induced Nausea and Vomiting, which was approved for use by the FDA and EMA in 2004. He is the Founder of AMR Ireland (www.amr.ie), a network to help to address the global public health crisis that is Antimicrobial Resistance. In TU Dublin, he has supervised 19 PhD and MSc research students to completion. He is a Fellow of the Royal Society of Chemistry and the Institute of Chemistry in Ireland, as well as being a Chartered Chemist and Chartered Scientist. His research funders include SFI, IRC, EPA, EI, HEA (PRTLI), and TU Dublin. He has collaborative links with researchers in Ireland (UCC, RCSI, DCU, ICHEC, Maynooth University, and TCD) and Internationally (Germany, France, Netherlands, and the UK), as well as industry links with MNCs, including Ipsen, Henkel, and Glanbia.